Back to search results

Study of Radiation and Brentuximab Vedotin for Mycosis Fungoides

This study is looking at how effective a combination of ultra-low-dose total-skin electron beam therapy (ULD-TSEBT), a type of radiation, and a drug called brentuximab vedotin is for people with mycosis fungoides (a type of skin lymphoma). You may be able to join if you are 18 or older and have biopsy-confirmed mycosis fungoides in stages I-IV. The main goal is to see how many patients respond to this treatment over about one year. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will follow participants for complete response, progression-free survival, and overall survival for an expected two and a half years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05357794

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~30 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Brentuximab vedotin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To establish the overall response rate (ORR)
Measured over through study completion, an average of 1 year

Conditions

Mycosis Fungoides

Explore related trials

Mycosis FungoidesTNFRSF8 Gene

NCT05357794

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bouthaina Dabaja, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Bouthaina Dabaja, MD
[email protected]
(713) 563-2406
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation
oral
intravaginal
transdermal
Progestogen-only hormonal contraception associated with inhibition of ovulation
oral
injectable
Implantable progestogen-only hormonal contraception associated with inhibition of ovulation b
Intrauterine device (IUD)c
Intrauterine hormone-releasing system (IUS)c
Bilateral tubal occlusion
Surgical Sterilization 6. Receipt of systemic therapy for another primary malignancy (other than T-cell lymphoma). Participants with more than one type of lymphoma may be enrolled after discussion with the Principal Investigator 7. Underlying medical conditions including unstable cardiac disease, or other serious illness that would impair the ability of participants to undergo treatment 8. Any other medical history, including laboratory results, deemed by the Principal Investigator to be likely to interfere with participants participation in the study 9. Use of strong CYP3A4 inhibitors or inducers, or P-gp inhibitors, should be avoided given the potential effect on exposure to monomethyl auristatin E.

What this trial measures

  • To establish the overall response rate (ORR)through study completion, an average of 1 year